🔎 Trials Near Me

Domov › Rakovina obličiek (renálny bunkový karcinóm) › Washington

Klinické štúdie Rakovina obličiek (renálny bunkový karcinóm) v štáte Washington

12 štúdií pre Rakovina obličiek (renálny bunkový karcinóm) hľadá účastníkov v zariadeniach v štáte Washington.

Mestá v štáte Washington

Oficiálny text štúdie (anglicky)

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

  • Swedish Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • a 19 ďalších
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Valley Medical Center, Renton
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT03866382

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Fred Hutchinson Cancer Center, Seattle
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT04981119

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Northwest Medical Specialties, Tacoma
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06047379

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  • Local Institution - 0095, Seattle
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07293351

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  • Virginia Mason Medical Center, Seattle
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Fred Hutchinson Cancer Center, Seattle
  • University Of Washington Medical Center, Seattle
  • Northwest Cancer Specialists, P.C., Vancouver
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07227415

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Seattle
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT05433142

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  • Fred Hutch Cancer Center, Seattle
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2025 · NCT06682793

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Valley Medical Center, Renton
  • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2025 · NCT04510597

A Study of IBI363 in Subjects with Advanced Solid Malignancies

  • Fred Hutchinson Cancer Center, Seattle
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 19. 12. 2024 · NCT06281678

Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.